These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 30429879

  • 1. Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional Aβ deposition rate and plaque burden at treatment initiation.
    Brendel M, Jaworska A, Overhoff F, Blume T, Probst F, Gildehaus FJ, Bartenstein P, Haass C, Bohrmann B, Herms J, Willem M, Rominger A.
    Theranostics; 2018; 8(18):4957-4968. PubMed ID: 30429879
    [Abstract] [Full Text] [Related]

  • 2. Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment.
    Brendel M, Jaworska A, Herms J, Trambauer J, Rötzer C, Gildehaus FJ, Carlsen J, Cumming P, Bylund J, Luebbers T, Bartenstein P, Steiner H, Haass C, Baumann K, Rominger A.
    Mol Psychiatry; 2015 Oct; 20(10):1179-87. PubMed ID: 26055427
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease.
    Deleye S, Waldron AM, Verhaeghe J, Bottelbergs A, Wyffels L, Van Broeck B, Langlois X, Schmidt M, Stroobants S, Staelens S.
    J Nucl Med; 2017 Dec; 58(12):1977-1983. PubMed ID: 28611242
    [Abstract] [Full Text] [Related]

  • 4. Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition.
    Meier SR, Syvänen S, Hultqvist G, Fang XT, Roshanbin S, Lannfelt L, Neumann U, Sehlin D.
    J Nucl Med; 2018 Dec; 59(12):1885-1891. PubMed ID: 29853653
    [Abstract] [Full Text] [Related]

  • 5. BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology.
    Peters F, Salihoglu H, Rodrigues E, Herzog E, Blume T, Filser S, Dorostkar M, Shimshek DR, Brose N, Neumann U, Herms J.
    Acta Neuropathol; 2018 May; 135(5):695-710. PubMed ID: 29327084
    [Abstract] [Full Text] [Related]

  • 6. AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice.
    Eketjäll S, Janson J, Jeppsson F, Svanhagen A, Kolmodin K, Gustavsson S, Radesäter AC, Eliason K, Briem S, Appelkvist P, Niva C, Berg AL, Karlström S, Swahn BM, Fälting J.
    J Neurosci; 2013 Jun 12; 33(24):10075-84. PubMed ID: 23761903
    [Abstract] [Full Text] [Related]

  • 7. Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.
    Jacobsen H, Ozmen L, Caruso A, Narquizian R, Hilpert H, Jacobsen B, Terwel D, Tanghe A, Bohrmann B.
    J Neurosci; 2014 Aug 27; 34(35):11621-30. PubMed ID: 25164658
    [Abstract] [Full Text] [Related]

  • 8. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
    Brendel M, Delker A, Rötzer C, Böning G, Carlsen J, Cyran C, Mille E, Gildehaus FJ, Cumming P, Baumann K, Steiner H, Haass C, Herms J, Bartenstein P, Rominger A.
    Neuroimage; 2014 Jan 01; 84():843-53. PubMed ID: 24055703
    [Abstract] [Full Text] [Related]

  • 9. Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET.
    Rominger A, Brendel M, Burgold S, Keppler K, Baumann K, Xiong G, Mille E, Gildehaus FJ, Carlsen J, Schlichtiger J, Niedermoser S, Wängler B, Cumming P, Steiner H, Herms J, Haass C, Bartenstein P.
    J Nucl Med; 2013 Jul 01; 54(7):1127-34. PubMed ID: 23729696
    [Abstract] [Full Text] [Related]

  • 10. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
    Neumann U, Rueeger H, Machauer R, Veenstra SJ, Lueoend RM, Tintelnot-Blomley M, Laue G, Beltz K, Vogg B, Schmid P, Frieauff W, Shimshek DR, Staufenbiel M, Jacobson LH.
    Mol Neurodegener; 2015 Sep 03; 10():44. PubMed ID: 26336937
    [Abstract] [Full Text] [Related]

  • 11. Longitudinal evaluation of a novel BChE PET tracer as an early in vivo biomarker in the brain of a mouse model for Alzheimer disease.
    Rejc L, Gómez-Vallejo V, Joya A, Moreno O, Egimendia A, Castellnou P, Ríos-Anglada X, Cossío U, Baz Z, Passannante R, Tobalina-Larrea I, Ramos-Cabrer P, Giralt A, Sastre M, Capetillo-Zarate E, Košak U, Knez D, Gobec S, Marder M, Martin A, Llop J.
    Theranostics; 2021 Sep 03; 11(13):6542-6559. PubMed ID: 33995675
    [Abstract] [Full Text] [Related]

  • 12. The BACE1-Specific DNA Aptamer A1 Rescues Amyloid-β Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease.
    Liang ZM, Peng YH, Chen Y, Long LL, Luo HJ, Chen YJ, Liang YL, Tian YH, Li SJ, Shi YS, Zhang XM.
    Nucleic Acid Ther; 2019 Dec 03; 29(6):359-366. PubMed ID: 31513457
    [Abstract] [Full Text] [Related]

  • 13. [18F]-florbetaben PET/CT Imaging in the Alzheimer's Disease Mouse Model APPswe/PS1dE9.
    Stenzel J, Rühlmann C, Lindner T, Polei S, Teipel S, Kurth J, Rominger A, Krause BJ, Vollmar B, Kuhla A.
    Curr Alzheimer Res; 2019 Dec 03; 16(1):49-55. PubMed ID: 30345916
    [Abstract] [Full Text] [Related]

  • 14. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.
    Georgievska B, Gustavsson S, Lundkvist J, Neelissen J, Eketjäll S, Ramberg V, Bueters T, Agerman K, Juréus A, Svensson S, Berg S, Fälting J, Lendahl U.
    J Neurochem; 2015 Feb 03; 132(4):477-86. PubMed ID: 25156639
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Passive immunotherapy with a novel antibody against 3pE-modified Aβ demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice.
    Janssens J, Hermans B, Vandermeeren M, Barale-Thomas E, Borgers M, Willems R, Meulders G, Wintmolders C, Van den Bulck D, Bottelbergs A, Ver Donck L, Larsen P, Moechars D, Edwards W, Mercken M, Van Broeck B.
    Neurobiol Dis; 2021 Jul 03; 154():105365. PubMed ID: 33848635
    [Abstract] [Full Text] [Related]

  • 19. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
    May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, Cocke PJ, Greg Hall D, Friedrich S, Citron M, Audia JE.
    J Neurosci; 2011 Nov 16; 31(46):16507-16. PubMed ID: 22090477
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.